- LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis(2017)
Authors: Sara Elashkar, Jonas Demeulemeester, Frauke Christ, Siska Van Belle, Nancy Boeckx, Zeger Debyser, Jan De Rijck
Pages: 95 - 107
- Artificial IN-peptide fusions provide BET-independent MLV-vectors with a safer integration profile(2016)
Authors: Dominique Van Looveren, Sara Elashkar, F Schenk, Lenard Vranckx, Jan De Rijck, Zeger Debyser, U Mödlich, Rik Gijsbers
Pages: A182 - A182
- Validation of the MLL-LEDGF/p75 interaction as a therapeutic target for Mixed Lineage Leukemia(2016)
Authors: Sara Elashkar, Jan De Rijck, Katerina Cermakova, Petr Tesina, Jonas Demeulemeester, Helene Mereau, Jürg Schwaller, Vaclav Ververka, Pavlina Rezacova, Zeger Debyser
Pages: S69 - S69
- Validation and structural characterisation of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia(2014)
Authors: Katerina Cermakova, Jonas Demeulemeester, Sara Elashkar, Jan De Rijck
Pages: 5139 - 5151
- Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia(2014)
Authors: Katerina Cermakova, Petr Tesina, Jonas Demeulemeester, Sara Elashkar, Helene Mereau, Juerg Schwaller, Pavlina Rezacova, Vaclav Veverka, Jan De Rijck
Pages: 5139 - 5151
- BET-independent MLV-based vectors target away from promoters and regulatory elements(2014)
Authors: Sara Elashkar, Jan De Rijck, Jonas Demeulemeester, Sofie Vets, Paradise Madlala, Katerina Cermakova, Zeger Debyser, Rik Gijsbers
- Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia(2014)
Authors: Katerina Cermakova, Petr Tesina, Jonas Demeulemeester, Sara Elashkar, Helene Mereau, Juerg Schwaller, Pavlina Rezacova, Vaclav Veverka, Jan De Rijck
Pages: 5139 - 5151